Shares of Protagonist Therapeutics (PTGX) surged 30% after reports of interest from J&J (JNJ) in acquiring the company. Discussions are ongoing, with no terms disclosed. PTGX is a clinical-stage company with a pipeline of novel peptides, including the potentially FDA-approved drug icotrokinra for plaque psoriasis. The stock has risen 125% year to date.

J&J’s interest in PTGX is driven by declining sales of Stelara and the need to diversify its revenue. The potential deal would give J&J a foothold in the immunology and hematology spaces. Recent M&A activity in the pharma sector, like Pfizer’s acquisition of Metsera and Roche’s deal with 89bio, reflects a trend of big companies seeking innovative assets.

Protagonist Therapeutics currently holds a Zacks Rank #3 (Hold). The reported interest from J&J highlights the potential for a strategic acquisition. In the rapidly evolving landscape of pharmaceuticals, such acquisitions can drive growth and innovation. Stay informed about emerging trends and opportunities in the market for potential investment decisions.

Read more at Nasdaq: Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal